Robust clinical evidence supports significant weight loss and cardiometabolic benefits for eligible patients
Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial
You are past the initial loading phases and approaching the upper end of escalation
22, 23, 41 Inhibition of PDE4 and PDE5 results in bronchodilation whereas inhibition of PDE4 contributes to its antiinflammatory effects
[DOI] [PubMed] [Google Scholar] 15.National Research Council
This article collates the latest evidence supporting GLP-1 use for weight loss, including trials in which they are being evaluated, while signposting to relevant articles from The Pharmaceutical Journal for detailed information related to their safe and effective use